Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: Bayer AG
Woman and Man Max 99 years
Bayer AG
Update Il y a 4 ans
A study investigating the efficacy and safety of anetumab ravtansine as 2nd line treatment for malignant pleural mesothelioma
Test the superiority of anetumab ravtansine monotherapy over vinorelbine in progression-free survival (PFS)
Country
None
organs
None
Specialty
None
unknown
More information
Woman Max 99 years
Bayer AG
Update Il y a 4 ans
Study of radium-223 dichloride versus placebo and hormonal treatment as background therapy in subjects with bone predominant HER2 negative hormone receptor positive metastatic breast cancer
To assess the efficacy and safety of radium-223 dichloride in subjects with HER2 negative, hormone receptor positive breast cancer with bone metastases treated with hormonal treatment background thera...
Country
None
organs
None
Specialty
None
unknown
More information
Woman Max 99 years
Bayer AG
Update Il y a 4 ans
Assess Safety and Efficacy of Vilaprisan in Subjects with Uterine Fibroids
The primary objective of this study is to assess the efficacy of vilaprisan in subjects with uterine fibroids compared to ulipristal.
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Bayer AG
Update Il y a 4 ans
To assess safety and tolerability, clinical effects of riociguat. To provide access to riociguat for patients with in-operable chronic thromboembolic pulmonary hypertension (CTEPH), or recurrent or persisting pulmonary hypertension (PH) after surgical treatment who are not satisfactorily treated and cannot participate in any other CTEPH trial
•To assess safety and tolerability, clinical effects of riociguat.. •To provide access to riociguat for patients with in-operable chronic thromboembolic pulmonary hypertension (CTEPH), or recurrent o...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Bayer AG
Update Il y a 4 ans
The ARRIVE Study (Aspirin to Reduce Risk of Initial Vascular Events) - A Randomized, Double-Blind, Placebo Controlled, Multicenter, Parallel Group Study to Assess the Efficacy (Reduction of Cardiovascular Disease Events) and Safety of 100 mg Enteric-Coated Acetylsalicylic Acid in Patients at Moderate Risk of Cardiovascular Disease
To evaluate the clinical effect of a 100 mg/day enteric coated aspirin vs placebo in the reduction of CVD events in patients at moderate risk of CHD events (approx 10 - 20% 10 year-risk). This corresp...
Country
None
organs
None
Specialty
None
unknown
More information
Man Max 99 years
Bayer AG
Update Il y a 4 ans
ODM-201 in addition to standard hormone therapy and docetaxel in metastatic hormone-sensitive prostate cancer
• To demonstrate the superiority in overall survival of ODM-201 in addition to standard androgen deprivation therapy (ADT) and docetaxel over placebo in addition to standard ADT and docetaxel
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Bayer AG
Update Il y a 4 ans
Managing neovascular age-related macular degeneration over 2 years using of different schedules of 2 mg aflibercept injected in the eye (ARIES)
To assess whether 2 mg IVT aflibercept administered in an early-start T&E regimen (initiated after the first 8-weekly treatment interval) is non-inferior to 2 mg IVT aflibercept administered in a late...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Bayer AG
Update Il y a 4 ans
A phase II trial to study neladenoson bialanate over 20 weeks in patients with chronic heart failure with reduced ejection fraction
Find the optimal dose of neladenoson bialanate for the Phase III trial by detecting and characterizing a significant dose-response relationship in the two primary efficacy endpoints, absolute change f...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Bayer AG
Update Il y a 4 ans
A study investigating copanlisib in combination with standard treatment versus standard treatment alone in order to see if copanlisib improves the response to standard treatment in patients with relapsed indolent non-Hodgkin's lymphoma
Safety run-in part Primary objective is to determine: The recommended phase III dose (RP3D) of copanlisib in combination with standard immunochemotherapy (rituximab and bendamustine [RB] or rituxima...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Bayer AG
Update Il y a 4 ans
A study investigating the efficacy and safety of copanlisib in combination with rituximab in patients with relapsed indolent B-cell non-Hodgkin's lymphoma
The primary objective of this study is: • To evaluate whether copanlisib in combination with rituximab is superior to placebo in combination with rituximab in prolonging progression free survival (PF...
Country
None
organs
None
Specialty
None
unknown
More information
Previous
1
2
3
4
Next